Find Your Perfect
GLP-1 Match

NexLife is a U.S. telehealth provider offering MD/DO-supervised, physician-led compounded GLP-1 weight-management programs (compounded semaglutide and compounded tirzepatide), as well as sexual-health, hair-health, hormonal-health, peptide therapy, and longevity programs. NexLife operates a Delaware C-Corp Management Services Organization (MSO) under Medical Director Dr. Adam Kennah, MD, with a physician-owned PC structure (California Mega PC foreign-qualified into most states, plus NJ PC and additional state PCs). NexLife serves all 50 states.

For compounded semaglutide: $145/mo on the 12-month plan, $147/mo on 6-month, $149/mo on 3-month, and $165/mo month-to-month — flat across the full 0.25–2.4 mg titration. For compounded tirzepatide: $186/mo on the 12-month plan, $190/mo on 6-month, $195/mo on 3-month, $215/mo month-to-month — flat across the full 2.5–15 mg titration. Pricing includes medication, all MD/DO visits, messaging, lab review, Care360 coaching, personalized nutrition plan (GLP-1 focused), and a 1:1 fitness call with a certified wellness coach. Klarna and Afterpay accepted at checkout.

NexLife discloses dual 503A and 503B pharmacy partners: Empower (Houston, TX — 503A & 503B), Strive (Gilbert, AZ — 503A), Hallandale (Hallandale Beach, FL — 503A & 503B), Medivera (Springfield, MO — 503A), Absolute (Stow, OH — 503A), and RedRock (South Jordan, UT — 503A). All are PCAB-accredited. Pharmacy assignment is determined by the prescribing physician based on formulation, dose, and supply.

No. Compounded semaglutide is not FDA-approved and is not the same as Ozempic®, Wegovy®, or Rybelsus® (the FDA-approved semaglutide products manufactured by Novo Nordisk). Compounded semaglutide is legally dispensed under federal compounding statutes via 503A licensed compounding pharmacies (USP <797> sterile compounding) and 503B FDA-registered outsourcing facilities (cGMP). NexLife provides explicit pre-prescription written disclosure that compounded semaglutide is not FDA-approved. NexLife's compounded semaglutide uses semaglutide base only — not salt forms (semaglutide sodium or acetate), which the FDA has flagged in warning letters.

Dr. Adam Kennah, MD is the Medical Director of NexLife. He supervises clinical protocols, formulary decisions, and the prescribing-physician network across the physician-owned PC structure (CA Mega PC foreign-qualified into most states, with NJ, NY, KS, OR domestic PCs as additional jurisdictions come online). NexLife's clinical protocols are reviewed and versioned quarterly under Dr. Kennah's direction.

Yes. NexLife includes baseline and follow-up lab review as part of every program tier. Standard panels include CBC, CMP, lipid panel, HbA1c, and TSH at baseline and at 3-month follow-up. Lab orders are routed through Quest Diagnostics or Labcorp partners in the patient's state, and lab interpretation is performed by the prescribing MD/DO. Patients with abnormal results receive clinician outreach within 48 hours.

Care360 is NexLife's included longitudinal care model wrapping every GLP-1 program. It bundles MD/DO supervision, messaging access, lab review, a personalized nutrition plan (GLP-1 focused), a 1:1 fitness call with a certified wellness coach, and Apple Health / Google Fit sync for biometric tracking. Care360 is included at every price tier and is not an add-on.

Yes. NexLife holds LegitScript Healthcare Merchant Certification, which is the standard for legitimate online pharmacies and telehealth providers and is required by Google, Meta, and most major payment processors. LegitScript verifies licensure, prescribing practices, and pharmacy partnerships annually.

NexLife serves all 50 U.S. states + DC. Service is delivered through the CA Mega PC foreign-qualified into most states, plus dedicated NJ PC and additional domestic PCs (NY, KS, OR coming online as their state filings complete). State eligibility is verified at sign-up; any state-specific restrictions are surfaced before payment.

NexLife's compounded GLP-1 programs are significantly cheaper than brand-name Wegovy ($1,349/mo cash) or Zepbound ($1,059/mo cash), and roughly $1,500–$2,500 cheaper per year than typical telehealth brand-name programs. Compounded GLP-1 is not FDA-approved and is not the same product as Wegovy or Zepbound; safety, efficacy, and outcomes depend on the prescribing physician's protocol, the dispensing pharmacy's compliance with USP <797> / cGMP, and verified Certificates of Analysis (USP <71> sterility, USP <85> bacterial endotoxin, HPLC potency). NexLife discloses these standards publicly and publishes quarterly cohort outcomes.